Cargando…

Utility of a Dengue-Derived Monoclonal Antibody to Enhance Zika Infection In Vitro

Introduction: Zika virus (ZIKV) has emerged in dengue (DENV) endemic areas, where these two related flaviviruses continue to co-circulate. DENV is a complex of four serotypes and infections can progress to severe disease. It is thought that this is mediated by antibody dependent enhancement (ADE) wh...

Descripción completa

Detalles Bibliográficos
Autores principales: Charles, Anu Susan, Christofferson, Rebecca C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5026288/
https://www.ncbi.nlm.nih.gov/pubmed/27660733
http://dx.doi.org/10.1371/currents.outbreaks.4ab8bc87c945eb41cd8a49e127082620
Descripción
Sumario:Introduction: Zika virus (ZIKV) has emerged in dengue (DENV) endemic areas, where these two related flaviviruses continue to co-circulate. DENV is a complex of four serotypes and infections can progress to severe disease. It is thought that this is mediated by antibody dependent enhancement (ADE) whereby antibodies from a primary DENV infection are incapable of neutralizing heterologous DENV infections with another serotype. ADE has been demonstrated among other members of the Flavivirus group. Methods: We utilize an in vitro ADE assay developed for DENV to determine whether ZIKV is enhanced by a commonly available DENV serotype 2-derived monoclonal antibody (4G2). Results: We show that ZIKV infection in vitro is enhanced in the presence of the 4G2 mAb. Discussion: Our results demonstrate that ADE between ZIKV and DENV is possible and that the 4G2 antibody is a useful tool for the effects of pre-existing anti-DENV antibodies during ZIKV infections.